Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats

Abstract

Acetaminophen has a reasonable safety profile when consumed in therapeutic doses. However, it could induce hepatotoxicity and even acute liver failure when taken at an overdose. Pioglitazone, PPARγ ligand, is clinically tested and used in treatment of diabetes. PPARγ is a key nuclear hormone receptor of lipid metabolisms and regulates several gene transcriptions associated with differentiation, growth arrest, and apoptosis. The aim of our study was to evaluate the hepatoprotective activity of pioglitazone on acetaminophen-induced hepatotoxicity and to understand the relationship between the PPARγ and acetaminophen-induced hepato injury. For the experiment, Sprague-Dawley rats (160-180 g) were used and divided into four groups. Groups I and II were normal and experimental controls, respectively. Groups III and IV received the pioglitazone 20 mg/kg for 10 days. Hepatotoxicity was induced in Groups II and III on the eighth day with acetaminophen (i.p. 350 mg/kg body weight). The hepatoprotective effect was evaluated by performing an assay of the total protein, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and α-fetoprotein as well as glutathione peroxidase, lipid peroxidation, catalase, superoxide dismutase, and glutathione transferase and liver histopathology. The assay results were presented as mean and standard error of mean for each group. The study group was compared with the control group by one-way ANOVA test. A p value of <0.05 was considered significant. Pioglitazone significantly reduced the elevated level of above serum marker enzymes and also inhibits the free radical formation by scavenging hydroxyl ions. It also restored the level of LPO and significantly elevated the levels of endogenous antioxidant enzymes in acetaminophen-challenged hepatotoxicity. Liver histopathological examination showed that pioglitazone administration antagonized acetaminophen -induced liver pathological damage. Various biochemical estimations of different hepatic markers and antioxidant enzymes and histopathological studies of liver tissues glimpse a support to its significant hepatoprotective activity on acetaminophen -induced hepatotoxicity.

Cardioprotective role of metformin against sodium arsenite‐induced oxidative stress, inflammation, and apoptosis

“…The primary discoveries of this investigation demonstrated that the Met administration to the experimental animals lessened OS, inflammation, apoptosis, and histopathological changes. It was entrenched that the expanded OS seen in heart tissue because of arsenic exposure may be a primary etiology for arsenic‐prompted cardiotoxicity . The conceivable metabolic mechanism of arsenic‐incited heart injury may be because of the fragmentation of DNA, ROS, changes in cardiac ion channels, and apoptosis.…”

Effect of sitagliptin, a DPP‐4 inhibitor, against DENA‐induced liver cancer in rats mediated via NF‐κB activation and inflammatory cytokines

“…SGPT enzyme is more particular to evaluate an injury in a liver as SGOT is also elevated in heart attack or muscle injury. Increased level of SALP is a marker of hepatobiliary injury …”

“…After formation, bilirubin transfers into the liver and then is released from the liver into the bile. For its release into bile, a conjugation of bilirubin is required …”

“…Similarly, in a lipid profile examination, levels of serum TC and TG were significantly elevated as well as values of serum HDLs were reduced in DENA‐exposed rats. The alteration in lipid profile may be due to the accumulation of TG, inhibition of synthesis of bile acid from cholesterol that is synthesized in the liver or obtained from plasma lipids, leading to rise in a level of cholesterol …”

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease

“…The adverse effects of each PPAR agonist are summarized in Table I. In order to overcome these adverse effects, many researchers found that dual PPAR agonists could improve liver injury without side effects induced by single PPAR agonists (13,(61)(62)(63). Clinical trials also demonstrated that PPAR agonist therapies may lead to side effects such as paradoxical dissociation of steatosis, inflammation, etc.…”